CTLA4 and cancer: Interestingly, some studies show that the primary response to anti-CTLA4 antibodies required a high-level exposure of MHC-1 on the surface of cancer cells at baseline; on the other hand, the response to anti-PD-1 antibodies is linked to a pre-existing IFNγ transcriptome signature [219].